Clinical Trends for October 2015

Ryan Syrek

Disclosures

October 30, 2015

Physicians search to find clinical information and keep current. Each week, we look for a term that dramatically increased in physician searches from the week prior, based on significance and percentage of increase. Although sometimes driven by what's in the news, the possible reasons why a term surged in popularity may surprise you. We speculate as to what prompted the increase and provide an interesting fact about the related medical condition with an infographic. If you have thoughts about what's trending and why, feel free to share them with us on Twitter or Facebook!

Clinical Trend of the Week (October 23-30): Praxbind

The US Food and Drug Administration gave accelerated approval to a drug that reverses a drug. That is to say, this week's top search term, Praxbind (idarucizumab), was approved to combat the blood-thinning effects of dabigatran (Pradaxa). Pradaxa is a key tool in preventing stroke and blood clots in those with atrial fibrillation and is also used in the treatment and prevention of deep venous thrombosis and pulmonary embolism. However, reversing that drug's effects is sometimes medically necessary. Given the potential life-saving nature of both drugs, it is no wonder physicians searched for more information on the subject.

For more in-depth clinical information, see Atrial Fibrillation.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....